GreenLight Biosciences (Nasdaq: ENVI), a US-based biotechnology company, and Samsung Biologics (KRX: 207940.KS), a Korea-based global CDMO offering completely integrated end-to-end contract development and manufacturing services, announced on Wednesday that they have entered into a collaboration agreement for the production of GreenLight's messenger RNA COVID-19 vaccine candidate at commercial scale.
The collaboration intends to expedite production of GreenLight's COVID-19 vaccine candidate for Phase III clinical trials and is subject to regulatory approval for commercial sales. It will use GreenLight's present manufacturing process, with technology transfer from GreenLight Biosciences to Samsung Biologics commencing immediately.
GreenLight CEO Andrey Zarur, said, 'We are delighted to partner with Samsung to manufacture messenger RNA for our Covid vaccine trial. There is an urgent need to develop vaccines for the whole world. Our vaccine trial will open the way to make vaccines that are available to everybody, not just citizens of developed countries.'
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine